Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ILM24
- Development stage
- Preclinical
- Lead developer
- Illimis Therapeutics
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
ILM24 is a preclinical-stage GAS6-based fusion protein being developed by Illimis Therapeutics for the treatment of systemic lupus erythematosus (SLE). Developed using the company's proprietary GAIA (Gas6-mediated Anti-Inflammatory Adaptor) platform, ILM24 is designed to target phosphatidylserine (PS). The therapeutic mechanism involves promoting the inflammation-silent phagocytic clearance of phosphatidylserine-positive material, leveraging TAM (Tyro3, Axl, and Mer) receptor biology to clear apoptotic debris and suppress inflammatory responses without triggering unwanted systemic inflammation.
02
Targets
MERTK (MER proto-oncogene, tyrosine kinase)AXL (AXL receptor tyrosine kinase)
Beyond the preview
Go deeper on ILM24.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ILM24.